Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis

Stegmayr, Bernd ; Newman, Elizabeth ; Witt, Volker ; Derfler, Kurt ; Leitner, Gerda ; Eloot, Sunny ; Dhondt, Annemieke ; Deeren, Dries ; Ptak, Jan and Blaha, Milan , et al. (2021) In Transfusion Medicine and Hemotherapy 48(4). p.234-239
Abstract

Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from >104,000 procedures were documented, and TA was performed on >15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11%... (More)

Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from >104,000 procedures were documented, and TA was performed on >15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11% of patients. Patients with indications such as neurological diseases underwent plasma exchange (28%). Extracorporeal photochemotherapy, lipid apheresis, and antibody removal were other indications. Side effects recorded in the registry have decreased significantly over the years, with approximately only 10/10,000 procedures being interrupted for medical reasons. Conclusion: Collection of data from TA procedures within a multinational and multicenter concept facilitates the improvement of treatment by enabling the analysis of and feedback on indications, procedures, effects, and side effects.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adverse events, Apheresis, Diagnoses, Registry
in
Transfusion Medicine and Hemotherapy
volume
48
issue
4
pages
234 - 239
publisher
Karger
external identifiers
  • pmid:34539317
  • scopus:85099065691
ISSN
1660-3796
DOI
10.1159/000513123
language
English
LU publication?
no
id
258e2d5d-157a-4cd7-80f4-d298e2f00f08
date added to LUP
2021-01-21 11:09:34
date last changed
2024-05-30 05:11:03
@article{258e2d5d-157a-4cd7-80f4-d298e2f00f08,
  abstract     = {{<p>Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from &gt;104,000 procedures were documented, and TA was performed on &gt;15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11% of patients. Patients with indications such as neurological diseases underwent plasma exchange (28%). Extracorporeal photochemotherapy, lipid apheresis, and antibody removal were other indications. Side effects recorded in the registry have decreased significantly over the years, with approximately only 10/10,000 procedures being interrupted for medical reasons. Conclusion: Collection of data from TA procedures within a multinational and multicenter concept facilitates the improvement of treatment by enabling the analysis of and feedback on indications, procedures, effects, and side effects. </p>}},
  author       = {{Stegmayr, Bernd and Newman, Elizabeth and Witt, Volker and Derfler, Kurt and Leitner, Gerda and Eloot, Sunny and Dhondt, Annemieke and Deeren, Dries and Ptak, Jan and Blaha, Milan and Lanska, Mirka and Gasova, Zdenka and Bhuiyan-Ludvikova, Zdenka and Hrdlickova, Radomira and Ramlow, Wolfgang and Prophet, Heinrich and Kielstein, Jan T. and Liumbruno, Giancarlo and Mori, Elena and Griskevicius, Antanas and Audzijoniene, Judita and Vrielink, Hans and Rombout-Sestrienkova, Eva and Aandahl, Astrid and Sikole, Aleksandar and Tomaz, Jorge and Lalic, Katarina and Bojanic, Ines and Strineholm, Virginia and Brink, Bo and Berlin, Gösta and Dykes, Josefina and Nilsson, Thomas and Eich, Torsten and Hadimeri, Henrik and Welander, Gunilla and Ortega Sanchez, Sandra and Ilhan, Osman and Poole, Colwyn}},
  issn         = {{1660-3796}},
  keywords     = {{Adverse events; Apheresis; Diagnoses; Registry}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{4}},
  pages        = {{234--239}},
  publisher    = {{Karger}},
  series       = {{Transfusion Medicine and Hemotherapy}},
  title        = {{Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis}},
  url          = {{http://dx.doi.org/10.1159/000513123}},
  doi          = {{10.1159/000513123}},
  volume       = {{48}},
  year         = {{2021}},
}